- Home
- ALLO vs RLTY Comparison
ALLO vs RLTY Comparison
Compare ALLO & RLTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLO
- RLTY
- Stock Information
- Founded
- ALLO 2017
- RLTY 2022
- Country
- ALLO United States
- RLTY United States
- Employees
- ALLO N/A
- RLTY N/A
- Industry
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- RLTY Investment Managers
- Sector
- ALLO Health Care
- RLTY Finance
- Exchange
- ALLO Nasdaq
- RLTY Nasdaq
- Market Cap
- ALLO 252.9M
- RLTY 255.0M
- IPO Year
- ALLO 2018
- RLTY N/A
- Fundamental
- Price
- ALLO $1.13
- RLTY $15.47
- Analyst Decision
- ALLO Strong Buy
- RLTY
- Analyst Count
- ALLO 10
- RLTY 0
- Target Price
- ALLO $8.88
- RLTY N/A
- AVG Volume (30 Days)
- ALLO 3.0M
- RLTY 86.7K
- Earning Date
- ALLO 11-06-2025
- RLTY 01-01-0001
- Dividend Yield
- ALLO N/A
- RLTY 9.35%
- EPS Growth
- ALLO N/A
- RLTY N/A
- EPS
- ALLO N/A
- RLTY N/A
- Revenue
- ALLO N/A
- RLTY N/A
- Revenue This Year
- ALLO N/A
- RLTY N/A
- Revenue Next Year
- ALLO $100.00
- RLTY N/A
- P/E Ratio
- ALLO N/A
- RLTY N/A
- Revenue Growth
- ALLO N/A
- RLTY N/A
- 52 Week Low
- ALLO $0.86
- RLTY $11.38
- 52 Week High
- ALLO $3.78
- RLTY $14.60
- Technical
- Relative Strength Index (RSI)
- ALLO 47.86
- RLTY 47.93
- Support Level
- ALLO $1.09
- RLTY $15.42
- Resistance Level
- ALLO $1.21
- RLTY $15.83
- Average True Range (ATR)
- ALLO 0.07
- RLTY 0.17
- MACD
- ALLO 0.01
- RLTY -0.01
- Stochastic Oscillator
- ALLO 33.33
- RLTY 13.35
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
About RLTY Cohen & Steers Real Estate Opportunities and Income Fund of Beneficial Interest
Cohen & Steers Real Estate Opportunities and Income Fund is an organized, non-diversified, closed-end management investment company. The Fund's primary investment objective is high current income. The Fund's secondary investment objective is capital appreciation.